ATE277629T1 - Morphogenische behandlung des chronischen nierenversagens - Google Patents
Morphogenische behandlung des chronischen nierenversagensInfo
- Publication number
- ATE277629T1 ATE277629T1 AT97922726T AT97922726T ATE277629T1 AT E277629 T1 ATE277629 T1 AT E277629T1 AT 97922726 T AT97922726 T AT 97922726T AT 97922726 T AT97922726 T AT 97922726T AT E277629 T1 ATE277629 T1 AT E277629T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- chronic kidney
- kidney failure
- risk
- morphogenic
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
- 230000000921 morphogenic effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- 238000012959 renal replacement therapy Methods 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/643,321 US6498142B1 (en) | 1996-05-06 | 1996-05-06 | Morphogen treatment for chronic renal failure |
| PCT/US1997/007816 WO1997041881A1 (en) | 1996-05-06 | 1997-05-06 | Morphogen treatment for chronic renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE277629T1 true ATE277629T1 (de) | 2004-10-15 |
Family
ID=24580305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97922726T ATE277629T1 (de) | 1996-05-06 | 1997-05-06 | Morphogenische behandlung des chronischen nierenversagens |
| AT97923567T ATE245997T1 (de) | 1996-05-06 | 1997-05-06 | Therapien des chronischen nierenversagens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97923567T ATE245997T1 (de) | 1996-05-06 | 1997-05-06 | Therapien des chronischen nierenversagens |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US6498142B1 (enExample) |
| EP (2) | EP0910400B1 (enExample) |
| JP (4) | JP2000510835A (enExample) |
| AT (2) | ATE277629T1 (enExample) |
| AU (2) | AU2832297A (enExample) |
| CA (2) | CA2254953C (enExample) |
| DE (2) | DE69723845T2 (enExample) |
| DK (2) | DK0910400T3 (enExample) |
| ES (2) | ES2230604T3 (enExample) |
| PT (2) | PT914146E (enExample) |
| WO (2) | WO1997041881A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| CA2363965C (en) * | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| WO1998050060A1 (en) * | 1997-05-05 | 1998-11-12 | Creative Biomolecules, Inc. | Therapies for acute renal failure |
| WO1998050061A1 (en) * | 1997-05-07 | 1998-11-12 | Biogen, Inc. | Novel therapies for cystic kidney disease |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| US6203788B1 (en) * | 1997-09-29 | 2001-03-20 | Adherex Inc. | Compounds and methods for regulating cell adhesion |
| EP1037910A2 (en) * | 1997-12-04 | 2000-09-27 | Curis, Inc. | Maintenance of smooth muscle integrity by morphogenic proteins |
| AU765832B2 (en) * | 1998-07-28 | 2003-10-02 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-11 |
| US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
| US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
| JP4975922B2 (ja) * | 1999-09-14 | 2012-07-11 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療 |
| US20020173453A1 (en) * | 2000-12-15 | 2002-11-21 | Rama Akella | Method of treating renal injury |
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7232802B2 (en) * | 2001-12-21 | 2007-06-19 | Zimmer Orthobiologics, Inc. | Compositions and methods for promoting myocardial and peripheral angiogenesis |
| US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
| EP1578360A4 (en) * | 2002-08-28 | 2009-10-21 | Curis Inc | JOINT ADMINISTRATION OF MORPHOGENES AND ANGIOTENSIN ENZYME CONVERTING INHIBITORS FOR THE TREATMENT OF CHRONIC RENAL FAILURE |
| EP2441474B1 (en) | 2003-10-17 | 2015-08-05 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
| US7844367B2 (en) | 2003-12-23 | 2010-11-30 | Rain Bird Corporation | Code replacement for irrigation controllers |
| CA2557999C (en) | 2004-03-30 | 2013-11-12 | Ilypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| WO2005097825A2 (en) * | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| US20100150885A1 (en) * | 2005-06-01 | 2010-06-17 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| US7771995B2 (en) * | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| CA2629522A1 (en) * | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
| US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
| US20070196810A1 (en) * | 2006-01-24 | 2007-08-23 | Northfield Laboratories Inc. | Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells |
| US20080090765A1 (en) * | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| EP2035835B1 (en) | 2006-05-30 | 2011-12-28 | Antibodyshop A/S | Methods for rapid assessment of severity of a trauma |
| US7722665B2 (en) * | 2006-07-07 | 2010-05-25 | Graft Technologies, Inc. | System and method for providing a graft in a vascular environment |
| EP2574625B1 (en) * | 2006-07-21 | 2015-02-25 | HuBit genomix, Inc. | Remedy for renal disease |
| US20080255181A1 (en) * | 2006-12-15 | 2008-10-16 | University Of Heidelberg | Methods for treating podocyte-related disorders |
| WO2008134297A2 (en) * | 2007-04-24 | 2008-11-06 | Johnson & Johnson Regenerative Therapeutics, Llc | Engineered renal tissue |
| DE102007034580B4 (de) * | 2007-07-13 | 2012-11-08 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Biomaterial basierend auf einem hydrophilen polymeren Träger |
| US20090155245A1 (en) * | 2007-12-18 | 2009-06-18 | Fang Carrie H | Treatment for Organ Regeneration with Combination of Drug and Biologics |
| AU2009244308A1 (en) * | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| WO2009157165A1 (ja) * | 2008-06-24 | 2009-12-30 | 株式会社根本杏林堂 | 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法 |
| BRPI0917711A2 (pt) * | 2008-08-28 | 2017-06-20 | Astute Medical Inc | método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal |
| WO2010025434A1 (en) * | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN106370857A (zh) | 2008-10-21 | 2017-02-01 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| CN104076152B (zh) * | 2008-10-21 | 2017-04-19 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| JP5752600B2 (ja) | 2008-11-10 | 2015-07-22 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法 |
| CN103439510B (zh) * | 2008-11-22 | 2016-09-14 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| AU2010210535B2 (en) * | 2009-02-06 | 2015-12-10 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20100204124A1 (en) * | 2009-02-12 | 2010-08-12 | Mary Elizabeth Pecquet Goad | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members |
| WO2010093925A2 (en) * | 2009-02-12 | 2010-08-19 | Stryker Corporation | PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE |
| AU2010223268B2 (en) | 2009-03-12 | 2015-04-23 | Haase Investments Gmbh | Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity |
| WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| US8871459B2 (en) | 2009-08-07 | 2014-10-28 | Astute Medical, Inc. | Method for evaluating renal status by determining beta-2-glycoprotein 1 |
| US20110224410A1 (en) | 2009-09-17 | 2011-09-15 | Hile David | Buffers for Controlling the pH of Bone Morphogenetic Proteins |
| NZ599773A (en) | 2009-11-07 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102725636B (zh) | 2009-12-20 | 2015-04-01 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| CA2785038A1 (en) | 2009-12-22 | 2011-07-21 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
| CA2788826C (en) | 2010-02-05 | 2023-09-26 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2011162819A1 (en) | 2010-06-23 | 2011-12-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2539712A4 (en) | 2010-02-26 | 2013-09-18 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
| WO2011149962A1 (en) | 2010-05-24 | 2011-12-01 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| WO2012023113A2 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Designer osteogenic proteins |
| WO2013086359A1 (en) | 2011-12-08 | 2013-06-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN104822383A (zh) | 2012-10-08 | 2015-08-05 | 瑞立普萨公司 | 治疗高血压和高血钾症的钾结合剂 |
| EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| JP6681195B2 (ja) | 2013-01-17 | 2020-04-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
| CA2929831C (en) * | 2013-11-11 | 2020-04-14 | General Electric Company | Method for reducing error in rotor speed measurements |
| EP2944326B1 (en) | 2014-05-16 | 2018-11-21 | Cyanagen Srl | Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases |
| WO2016131052A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN109844526A (zh) | 2016-06-06 | 2019-06-04 | 机敏医药股份有限公司 | 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤 |
| IL308824A (en) | 2016-08-17 | 2024-01-01 | Factor Bioscience Inc | Nucleic acid products and methods of administration thereof |
| JP2019039673A (ja) * | 2017-08-22 | 2019-03-14 | セイコーエプソン株式会社 | 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4627839A (en) | 1985-11-21 | 1986-12-09 | American Hospital Supply Corporation | Patient controlled analgesia conversion |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| ES2113857T3 (es) | 1989-03-28 | 1998-05-16 | Genetics Inst | Composiciones osteoinductoras. |
| DE69132823T2 (de) | 1990-05-16 | 2002-07-18 | Genetics Institute, Inc. | Knochen- und knorpel-bildung hervorrufende proteine |
| JPH0426624A (ja) * | 1990-05-18 | 1992-01-29 | Tsumura & Co | 慢性腎不全改善剤 |
| DE69123582T2 (de) * | 1990-06-22 | 1997-05-15 | E.I. Du Pont De Nemours & Co., Wilmington, Del. | Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten |
| US6194376B1 (en) | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| US7056882B2 (en) | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| CA2363965C (en) | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| AU660019B2 (en) | 1991-03-11 | 1995-06-08 | Stryker Corporation | Protein-induced morphogenesis |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| DE69233559T2 (de) | 1991-08-30 | 2006-08-31 | Curis, Inc., Cambridge | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten |
| ATE197611T1 (de) | 1991-08-30 | 2000-12-15 | Creative Biomolecules Inc | Screeningverfahren von morphogenischen proteinen |
| CA2116562C (en) | 1991-08-30 | 1999-04-13 | Thangavel Kuberasampath | Morphogen-induced modulation of inflammatory response |
| US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| EP0653942B2 (en) | 1992-07-31 | 2007-03-07 | Curis, Inc. | Morphogen-induced nerve regeneration and repair |
| ES2118253T3 (es) | 1992-07-31 | 1998-09-16 | Creative Biomolecules Inc | Composicion dietetica enriquecida con morfogen. |
| AU678380B2 (en) | 1992-07-31 | 1997-05-29 | Stryker Corporation | Morphogenic protein soluble complex and composition thereof |
| EP0661987B1 (en) | 1992-09-16 | 1998-01-14 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| EP0672064A1 (en) | 1992-11-03 | 1995-09-20 | Creative Biomolecules, Inc. | Op-3-induced morphogenesis |
| US5372335A (en) | 1992-12-18 | 1994-12-13 | Scott H. Yenzer | Aerial marker ball and method of placement |
| WO1994020539A1 (en) | 1993-03-04 | 1994-09-15 | Creative Biomolecules, Inc. | Method and compositions for recombinant osteogenic protein production |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| JPH09509141A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法 |
| US5525621A (en) * | 1994-05-20 | 1996-06-11 | Cytos Pharmaceuticals Llc | Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US5723411A (en) * | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
| DE69723429T3 (de) | 1996-03-22 | 2007-09-20 | Curis, Inc., Cambridge | Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS |
| US5820589A (en) | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US5879908A (en) * | 1997-04-30 | 1999-03-09 | Smithkline Beecham Corporation | CRFG-1a, a target and marker for chronic renal failure |
| US7147839B2 (en) * | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1996
- 1996-05-06 US US08/643,321 patent/US6498142B1/en not_active Expired - Lifetime
-
1997
- 1997-05-06 DE DE69723845T patent/DE69723845T2/de not_active Expired - Lifetime
- 1997-05-06 DK DK97923567T patent/DK0910400T3/da active
- 1997-05-06 AU AU28322/97A patent/AU2832297A/en not_active Abandoned
- 1997-05-06 PT PT97922726T patent/PT914146E/pt unknown
- 1997-05-06 JP JP09540150A patent/JP2000510835A/ja active Pending
- 1997-05-06 DE DE69730966T patent/DE69730966T2/de not_active Expired - Lifetime
- 1997-05-06 JP JP54021197A patent/JP4766722B2/ja not_active Expired - Fee Related
- 1997-05-06 AT AT97922726T patent/ATE277629T1/de active
- 1997-05-06 US US08/851,628 patent/US6861404B1/en not_active Expired - Fee Related
- 1997-05-06 AT AT97923567T patent/ATE245997T1/de not_active IP Right Cessation
- 1997-05-06 EP EP97923567A patent/EP0910400B1/en not_active Expired - Lifetime
- 1997-05-06 AU AU29339/97A patent/AU2933997A/en not_active Abandoned
- 1997-05-06 CA CA002254953A patent/CA2254953C/en not_active Expired - Fee Related
- 1997-05-06 WO PCT/US1997/007816 patent/WO1997041881A1/en not_active Ceased
- 1997-05-06 EP EP97922726A patent/EP0914146B1/en not_active Expired - Lifetime
- 1997-05-06 ES ES97922726T patent/ES2230604T3/es not_active Expired - Lifetime
- 1997-05-06 CA CA002254954A patent/CA2254954C/en not_active Expired - Fee Related
- 1997-05-06 DK DK97922726T patent/DK0914146T3/da active
- 1997-05-06 WO PCT/US1997/007655 patent/WO1997041880A1/en not_active Ceased
- 1997-05-06 PT PT97923567T patent/PT910400E/pt unknown
- 1997-05-06 ES ES97923567T patent/ES2203803T3/es not_active Expired - Lifetime
-
2004
- 2004-12-17 US US11/016,499 patent/US7524817B2/en not_active Expired - Fee Related
-
2009
- 2009-03-16 US US12/404,559 patent/US8017580B2/en not_active Expired - Fee Related
- 2009-05-26 JP JP2009126963A patent/JP5247593B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-11 US US13/207,584 patent/US8377878B2/en not_active Expired - Fee Related
-
2012
- 2012-08-14 JP JP2012179876A patent/JP2012229268A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69730966D1 (de) | Morphogenische behandlung des chronischen nierenversagens | |
| FI960809L (fi) | Hermoregeneraatio käyttäen ihmisen luun morfogeneettisiä proteiineja | |
| ATE278414T1 (de) | Therapien zur behandlung von akutem nierenversagen | |
| DE60020613D1 (de) | (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| HUP9802556A1 (hu) | Eljárás és készítmény kötőszöveti kapcsolódások gyógyítására és helyreállítására | |
| NO970536D0 (no) | Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate | |
| EP1095159A4 (en) | Bone Morphogenetic Protein | |
| FI956078A0 (fi) | Järjestelmä veren virusten inaktivoimiseksi | |
| ATE273031T1 (de) | Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen | |
| NO972391L (no) | 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
| FR2762985B1 (fr) | Dispositif de chirurgie modulaire pour la chirurgie endoscopique et la chirurgie classique | |
| ATE226442T1 (de) | Anti-chlamydia verfahren und mittel | |
| EP0871457A4 (en) | ISOLATED CURRENT CELLS AND METHODS FOR THE USE THEREOF | |
| DE69714451D1 (de) | Prionbindende proteine und deren verwendungen | |
| EP0960117A4 (en) | ON FIBROBLASTS GROWTH FACTOR HOMOLOGICAL FACTORS (FHFs) AND METHOD OF APPLICATION | |
| EP1169058A4 (en) | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 Protease | |
| DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| EP1185283A4 (en) | NEW THERAPEUTIC USE OF A VIRAL INJECTION MODULATING PROTEIN TO PREVENT EXHAUST FROM FOREIGN TRANSPLANTS | |
| DK0972520T3 (da) | Frysetörret sammensætning af humant, knoglemorfogenetisk protein MP52 | |
| ATE265225T1 (de) | Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
| PT1214091E (pt) | Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina | |
| ATE306275T1 (de) | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten | |
| ATE222479T1 (de) | Einheit zur knorpelreparatur | |
| FR2764389B1 (fr) | Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0914146 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |